Literature DB >> 35464507

Stereotactic Body Radiotherapy for a Sacral Metastasis Clarified by Diffusion-Weighted Whole-Body Imaging With Background Body Signal Suppression in a Patient With Castration-Resistant Prostate Cancer.

Atsuto Katano1, Kenta Takeuchi1, Hideomi Yamashita1, Keiichi Nakagawa1.   

Abstract

Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) is an emerging extended modality of diffusion-weighted imaging for screening malignant lesions in the body. A 70-year-old male was diagnosed with advanced-stage prostate adenocarcinoma with distant metastasis. After hormone therapy, the disease progressed to castration-resistant prostate cancer (CRPC). Serum prostate-specific antigen (PSA) levels increased during androgen deprivation therapy with low serum testosterone levels. 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) and technetium-99m methylene bone scintigraphy (BS) did not reveal obvious distant metastases; however, we were able to identify distant metastases by DWIBS. We herein report a case in which stereotactic body radiotherapy (SBRT) was performed on target lesions detected by DWIBS and successfully suppressed disease progression.
Copyright © 2022, Katano et al.

Entities:  

Keywords:  bone metastasis; castration-resistant prostate cancer; dwibs; oligometastases; stereotactic body radiotherapy

Year:  2022        PMID: 35464507      PMCID: PMC9001865          DOI: 10.7759/cureus.23047

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  13 in total

Review 1.  Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.

Authors:  Antonino Battaglia; Gert De Meerleer; Lorenzo Tosco; Lisa Moris; Thomas Van den Broeck; Gaëtan Devos; Wouter Everaerts; Steven Joniau
Journal:  Eur Urol Oncol       Date:  2018-10-09

2.  Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/CT-Identified Oligometastatic Castration-Resistant Prostate Cancer.

Authors:  Henan Zhang; Jacob J Orme; Haidong Dong; Sean S Park; Feven Abraha; B J Stish; Val J Lowe; Fabrice Lucien; Erik J Tryggestad; Michael S Bold; Lance C Pagliaro; C Richard Choo; Debra H Brinkmann; Matthew J Iott; Brian J Davis; J Fernando Quevedo; William S Harmsen; Brian A Costello; Geoffrey B Johnson; Mark A Nathan; Kenneth R Olivier; Thomas M Pisansky; Eugene D Kwon
Journal:  Clin Cancer Res       Date:  2021-09-30       Impact factor: 13.801

3.  Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display.

Authors:  Taro Takahara; Yutaka Imai; Tomohiro Yamashita; Seiei Yasuda; Seiji Nasu; Marc Van Cauteren
Journal:  Radiat Med       Date:  2004 Jul-Aug

4.  Non-metastatic CRPC and asymptomatic metastatic CRPC: which treatment for which patient?

Authors:  B Tombal
Journal:  Ann Oncol       Date:  2012-09       Impact factor: 32.976

5.  Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I.

Authors:  William T Lowrance; Rodney H Breau; Roger Chou; Brian F Chapin; Tony Crispino; Robert Dreicer; David F Jarrard; Adam S Kibel; Todd M Morgan; Alicia K Morgans; William K Oh; Matthew J Resnick; Anthony L Zietman; Michael S Cookson
Journal:  J Urol       Date:  2020-09-22       Impact factor: 7.450

6.  Quality of life measurement in bone metastases: A literature review.

Authors:  Sukirtha Tharmalingam; Edward Chow; Kristin Harris; Amanda Hird; Emily Sinclair
Journal:  J Pain Res       Date:  2008-10-01       Impact factor: 3.133

7.  Time to progression to castration-resistant prostate cancer after commencing combined androgen blockade for advanced hormone-sensitive prostate cancer.

Authors:  Satoshi Tamada; Taro Iguchi; Minoru Kato; Jumpei Asakawa; Kazuaki Kita; Sayaka Yasuda; Takeshi Yamasaki; Yudai Matsuoka; Kazuyuki Yamaguchi; Kentaro Matsumura; Ishun Go; Tetsuji Ohmachi; Tatsuya Nakatani
Journal:  Oncotarget       Date:  2018-12-11

8.  Diffusion-weighted whole-body imaging with background suppression (DWIBS) is effective and economical for detection of metastasis or recurrence of lung cancer.

Authors:  Katsuo Usuda; Shun Iwai; Aika Yamagata; Yoshihito Iijima; Nozomu Motono; Munetaka Matoba; Mariko Doai; Sohsuke Yamada; Yoshimichi Ueda; Keiya Hirata; Hidetaka Uramoto
Journal:  Thorac Cancer       Date:  2021-01-21       Impact factor: 3.500

9.  Whole-body diffusion-weighted imaging with background body signal suppression in the detection of osseous and extra-osseous metastases.

Authors:  Ahmed Abdel Razek; Ahmed Tawfik; Mariam Abdel Rahman; Saleh Teima
Journal:  Pol J Radiol       Date:  2019-11-12

10.  The prognostic power of 18F-FDG PET/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer (mCRPC) patients.

Authors:  Matteo Bauckneht; Francesco Bertagna; Maria Isabella Donegani; Rexhep Durmo; Alberto Miceli; Vincenzo De Biasi; Riccardo Laudicella; Giuseppe Fornarini; Alfredo Berruti; Sergio Baldari; Annibale Versari; Raffaele Giubbini; Gianmario Sambuceti; Silvia Morbelli; Domenico Albano
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-05-19       Impact factor: 5.554

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.